Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

1885 results about "Methyl Donors" patented technology

S-adenosylmethionine is the methyl group donor for DNA methylation and several nutrients are required for the production of S-adenosylmethionine. These methyl nutrients include vitamins (folate, riboflavin, vitamin B12, vitamin B6, choline) and amino acids (methionine, cysteine, serine, glycine).

Compounds

A compound of formula (I) or a pharmaceutically acceptable salt or hydrate thereof wherein X-Y is -NHSO2- or -SO2NH-; R1 is H, CN or alkyl; R2 is selected from COOH and a tetrazolyl group; R3 is selected from H, Cl and alkyl; R4 is selected from H and halo; R5 is selected from H, alkyl, haloalkyl, SO2-alkyl, Cl, alkoxy, OH, CN, hydroxyalkyl, alkylthio, heteroaryl, cycloalkyl, heterocycloalkyl and haloalkoxy; R6 is H; R7 is selected from H, CN, haloalkyl, halo, SO2-alkyl, optionally substituted heteroaryl, SO2NR14R15, CONR10R11 and alkyl; R8 is selected from H, alkyl, haloalkyl and halo; R9 is H or halo; and R10, R11, R12, R14, and R15 are H or alkyl; R13 is selected from alkyl, halo, alkoxy, CN, haloalkyl and OH; and m is 0-3. The compounds of formula (I) modulate ERAP1 (endoplasmic reticulum aminopeptidase 1) and are for use in treating proliferative, immune or inflammatory disorders, particularly cancer or leukemia. The compounds of formula (I) stimulate a neo-antigen directed immune response in the subject. A method for producing an antigen-presenting cell which presents a neo-antigen using compounds of formula (I) is disclosed. An immunogenic composition comprising an antigen-presenting cell is also disclosed. Exemplified compounds include 4-cyclopropyl-3-(N-(2-(morpholin-3-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid.
Owner:GREY WOLF THERAPEUTICS LTD

Treatment of prostate cancer

Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof. Another method includes: administering once-daily to the subject in need thereof, an oral load dose formulation having from 240 mg to 480 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof, and thereafter administering once-daily to the subject, an oral maintenance dose formulation having 80 mg to 160 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.
Owner:TAKEDA PHARMA CO LTD +1

Treatment of prostate cancer

Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof. Another method includes: administering once-daily to the subject in need thereof, an oral load dose formulation having from 240 mg to 480 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof, and thereafter administering once-daily to the subject, an oral maintenance dose formulation having 80 mg to 160 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.
Owner:TAKEDA PHARMA CO LTD +1

UTR (Untranslated Region) element NHP1 as well as construction method and application thereof

The invention provides an UTR element NHP1 as well as a construction method and application thereof, and relates to the technical field of mRNA. A 5 'UTR with a good expression effect is designed by integrating dominant sequences of a human high-expression gene and a pathogen natural UTR, a chimeric structure NHP1 with high ribosome load is predicted through a calculation model, a DNA sequence of the NHP1 is as shown in SEQ NO 1, and an RNA sequence of the NHP1 is as shown in SEQ NO 2; an EGFP report system is adopted on the DNA level to rapidly screen UTR; the translation efficiency is quantitatively evaluated on the RNA level through luciferase mRNA (N1-methyl pseudouridine modification); and the particle size is controlled by a microfluidic technology, so that the optimized UTR-mRNA is efficiently expressed after being delivered.
Owner:INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI

Kit and detection method for detecting Alzheimer disease related protein in human blood

The invention provides a kit and a detection method for detecting Alzheimer disease related proteins in human blood. The kit comprises a microsphere solution coupled with a p-Tau-217 capture antibody, a microsphere solution coupled with a p-Tau-231 capture antibody, a fluorescein PE coupling detection antibody solution and a diluent, the diluent is prepared from tris (hydroxymethyl) aminomethane, Triton X-100, sodium chloride and Proclin300; according to the kit provided by the invention, the accuracy of detecting the p-Tau-217 protein and the p-Tau-231 protein is improved by designing the microspheres, specifically detecting the p-Tau-217 protein and the p-Tau-231 protein and using a double-antibody sandwich detection method, clinical detection application is more convenient, and the kit is high in specificity, high in sensitivity, good in repeatability and relatively good in application prospect.
Owner:SUZHOU ZHIYAN MEDICAL TECHNOLOGY CO LTD

Preparation method of antibacterial degradable sponge material

The invention relates to the field of sponge materials, and provides an antibacterial degradable sponge material and a preparation method thereof. The material is prepared from protocatechuic acid modified quaternized chitosan, quaternary ammonium salt grafted gelatin, sodium alginate, polyhydroxybutyrate, polycaprolactone, a polylactic acid-glycolic acid copolymer, hexamethylene diisocyanate, a foaming agent, nano cellulose, vitamin E, polyethylene glycol, triethylamine and dimethylformamide. Protocatechuic acid and quaternized chitosan are subjected to amidation modification, and chitosan and gelatin are subjected to quaternization treatment by adopting 2, 3-epoxypropyl trimethyl ammonium chloride, so that the antibacterial property and biodegradability of the material are improved. In the material preparation process, through vacuum degassing, foaming vacuum degree and humidity control and a multi-step drying process, it is ensured that the average pore size of the material is uniform (50-200 microns) and the porosity is high (50%-90%), and the obtained material has excellent antibacterial property and degradability and has wide application value.
Owner:NANTONG FENGSHENG TEXTILE CO LTD

Filter membrane for removing DNA (deoxyribonucleic acid) pollution in water as well as preparation method and application of filter membrane

The invention relates to the technical field of water treatment, in particular to a filter membrane for removing DNA pollution in water and a preparation method and application thereof.The filter membrane comprises a matrix and an MOF material loaded on the matrix, the matrix comprises a nanocellulose fiber hydrogel membrane, the MOF material is formed by metal salt and organic ligands in a coordination mode, and the metal salt and the organic ligands are mutually bonded. The metal salt comprises at least one of a Zr source and an Hf source, the organic ligand comprises at least one of imidazole-4, 5-dicarboxylic acid, 1-methyl-1H-imidazole-4, 5-dicarboxylic acid (1MIA) and 2-methyl-1H-imidazole-4, 5-dicarboxylic acid, and the MOF material is optimally 1MIA-Zr. The filter membrane provided by the invention has excellent filtering performance, and can efficiently remove DNA pollution in water on the basis of filtering ultra-small particles in water, and the DNA degradation capacity of the filter membrane is 40 times that of reported materials (such as UiO-66 and the like) in the prior art.
Owner:CHANGCHUN INSTITUTE OF APPLIED CHEMISTRY CHINESE ACADEMY OF SCIENCES

Molecular marker related to content of 2-acetyl-3-methylpyrazine in pig muscle and application of molecular marker

The invention relates to a molecular marker related to the content of 2-acetyl-3-methylpyrazine in pig muscle and application of the molecular marker, belonging to the technical field of determination or inspection methods of enzymes, nucleic acids or microorganisms. The technical problem to be solved by the invention is to provide a molecular marker related to the content of 2-acetyl-3-methylpyrazine in pig muscle. In order to solve the technical problem, the molecular marker provided by the invention is obtained through genome-wide association (GWAS) analysis, the nucleotide sequence of the molecular marker is as shown in SEQ ID NO: 1, and the molecular marker has an Agt at the 6328556 position of a chromosome 9 of a pig genome; a nucleotide single base of G is mutated, and the mutation obviously affects the content of 2-acetyl-3-methylpyrazine in pig muscles. By detecting the genotype of a to-be-detected pig at the SNP site, early selection of the content of 2-acetyl-3-methylpyrazine in pig muscles can be realized.
Owner:INSTITUTE OF ANIMAL SCIENCES OF CHINESE ACADEMY OF AGRICULTURAL SCIENCES

Hydrogel loaded with oxygen self-producing nanoparticles as well as preparation method and application of hydrogel

The invention relates to hydrogel loaded with oxygen self-producing nanoparticles as well as a preparation method and application of the hydrogel. The preparation method comprises the following steps: 1, taking cross-linked methacrylamide silk fibroin and hyaluronic acid modified by arginine-glycine-aspartic acid peptide as base materials, and loading self-oxygen-producing nano particles CaO2 (at) PVP (at) Cu-EGCG, and the self-oxygen-producing nano particles CaO2 (at) PVP (at) Cu-EGCG are prepared by coating Cu-EGCG on calcium peroxide nano particles modified by PVP modified polyvinylpyrrolidone. The hydrogel can improve energy metabolism and regulate immune environment through dual mechanisms, realizes efficient promotion of myocardial repair, and provides a new strategy and thought for tissue regeneration and functional recovery after myocardial infarction.
Owner:BEOGENE BIOTECH GUANGZHOU

Cartilage organ constructed based on DNA-silk fibroin hybrid hydrogel sustained release system as well as preparation method and application of cartilage organ

The invention relates to a cartilage organ constructed on the basis of a DNA-silk fibroin hybrid hydrogel sustained-release system as well as a preparation method and application of the cartilage organ. The DNA-silk fibroin hybrid hydrogel sustained-release system is a hydrogel system formed by printing a DNA-silk fibroin hybrid hydrogel sustained-release system premix solution through a digital light processing system, and the DNA-silk fibroin hybrid hydrogel sustained-release system premix solution contains DNA, silk fibroin, acryloylated RGD peptide, acryloylated polyethylene glycol NHS ester, glucosamine, TD-198946 and 2, 4, 6-trimethyl-1, 3-pentanediol. The invention discloses a lithium 2, 6-trimethylbenzoyl phosphate. Compared with the prior art, the glucosamine and the TD-198946 introduced into the DNA-silk fibroin hybrid hydrogel sustained-release system disclosed by the invention can be used for remarkably improving and promoting the cartilage differentiation efficiency of the bone marrow mesenchymal stem cells; the cartilage graft can be transplanted to a cartilage defect position as a cartilage graft to promote cartilage regeneration and repair.
Owner:SHANGHAI UNIV +1

Fusion protein with tribasic group editing function and application thereof

The invention provides a fusion protein with a tribasic group editing function and application thereof, and relates to the technical field of basic group editing. The fusion protein comprises adenine deaminase, N-methylpurine DNA (deoxyribonucleic acid) glycosylase and nuclease. Aiming at the problem that an existing base editing tool cannot edit by taking three bases as substrates at the same time, the invention provides a novel three-function base editor which is named as A, Camp; and G-BE. A, Camp; the G-BE can be edited by independently using A, C and G as substrates to realize the editing activity of A-G / T / C, C-T / G / A and G-T / A / C, and can also be edited by simultaneously using A, C and G as substrates on alleles.
Owner:SUZHOU INST OF SYST MEDICINE

Ovarian protection composition containing ergothioneine and preparation method thereof

The invention discloses an ovarian protection composition containing ergothioneine and a preparation method of the ovarian protection composition, and relates to the technical field of ovarian protection compositions. The ovary protection composition containing the ergothioneine is prepared from the following components in parts by mass: 0.1 to 0.5 part of the ergothioneine, 0.05 to 1 part of S-equol, 1 to 5 parts of reducing coenzyme Q10, 1 to 3 parts of vitamin E, 10 to 20 parts of chitosan oligosaccharide, 30 to 50 parts of microcrystalline cellulose, 3 to 8 parts of hydroxypropyl methyl cellulose, 0.5 to 2 parts of silicon dioxide and 0.5 to 2 parts of a stabilizer. By adopting the stabilizer, photooxidation and hydrolysis of sensitive components are inhibited through molecular action, and the long-term stability of the composition in a humid and hot environment is remarkably improved in combination with the physical barrier action of silicon dioxide. Through the antioxidant synergistic effect of the ergothioneine and the vitamin E, the hormone regulation effect of the S-equol and the energy metabolism improvement effect of the coenzyme Q10, a multi-layer ovarian function protection system is constructed, and the health state of ovaries is improved. Through a special process, the tablet can be rapidly disintegrated and slowly released in an intestinal targeted manner, burst release of active ingredients is avoided, and the absorption efficiency is improved.
Owner:SHANGHAI ERGOTEIN BIOTECHNOLOGY GRP CO LTD

Modified porous chitosan gel bead, preparation method thereof and application of modified porous chitosan gel bead in cobalt-nickel separation

The invention provides a modified porous chitosan gel bead, a preparation method thereof and application of the modified porous chitosan gel bead in cobalt-nickel separation, and belongs to the technical field of chitosan preparation. The preparation method comprises the following steps: firstly, modifying chitosan by using polyethylene glycol and glutaraldehyde to obtain a porous chitosan gel bead with a cross-linked structure, and then grafting by using epichlorohydrin, ethylenediamine and 2-chloromethylpyridine hydrochloride to obtain the modified porous chitosan gel bead containing an aminomethylpyridine functional group. The modified porous chitosan gel bead has excellent selective adsorption on nickel ions in a cobalt-nickel solution with the pH value range of 2-5, and nickel-cobalt separation can be achieved. In addition, the modified porous chitosan gel bead also has a good nickel-cobalt separation effect in a salt-containing system. The preparation method of the modified porous chitosan gel bead provided by the invention is simple in process, and the raw material chitosan is wide in source, non-toxic and environment-friendly.
Owner:LANZHOU UNIV

2-(1h-indol-4-yl)methyl)-isoindoline derivatives as factor b inhibitors

The present invention relates to compounds (I) possessing an indole moiety linked to an isoindoline moiety, to compounds having similar core structures, and to associated salts, solvates, prodrugs and pharmaceutical compositions. The present invention further relates to methods of synthesising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by Factor B inhibition.
Owner:SITALA BIO LTD

Method for simultaneously determining contents of tolperidone hydrochloride, methyl hesperidin and vitamin B6 in Naoluotong capsule

PendingCN120121747AComponent separationVitamin b6Tolperisone Hydrochloride
The invention belongs to the field of pharmaceutical analysis, and discloses a method for simultaneously determining the contents of tolperidone hydrochloride, methyl hesperidin and vitamin B6 in Naoluotong capsules, the method comprises three steps of preparation of a mixed reference solution, preparation of a test solution and content determination, and the chromatographic conditions of the content determination are as follows: a C18 chromatographic column, a C18 chromatographic column, a C18 chromatographic column, a C18 chromatographic column, a C18 chromatographic column, a C18 chromatographic column, a C18 chromatographic column, a C18 chromatographic column and a C18 chromatographic column; a mobile phase is methanol (A)-0.1% glacial acetic acid solution (B), gradient elution is carried out for 0-5 min, and 96% of B is obtained; 5-6 min, 96%-60% of B is selected; 6-20 min, the content of B is 60%-50%; the volume flow rate is 1.0 ml / min; the column temperature is 30 DEG C; the detection wavelength is 291 nm; the sample size is 1 microliter. According to the method, synchronous detection of three components (tolperidone hydrochloride, methyl hesperidin and vitamin B6) with remarkable physicochemical property difference can be realized, the chromatographic condition is simple, and the detection speed is high.
Owner:ZHEJIANG INST FOR FOOD & DRUG CONTROL

Preparation method of sandwich structure immunosensor based on surface enhanced Raman scattering and application of sandwich structure immunosensor in detection of anti-phospholipase A2 receptor antibody

The invention discloses a preparation method of a sandwich structure immunosensor based on surface enhanced Raman scattering and application of the sandwich structure immunosensor to detection of an anti-phospholipase A2 receptor antibody, and is characterized by comprising the following steps: sputtering silver ions on a cotton swab / ZIF-67 prepared by an in-situ growth method by adopting an ion sputtering method to obtain a cotton swab / ZIF-67 / Ag NPs composite material; the preparation method comprises the following steps: preparing an antigen solution, then adding the antigen solution into the antigen solution to obtain an immune substrate, adding a methylene blue aqueous solution into a silver nanoparticle solution for reaction, then connecting an anti-human PLA2R IgG antibody to obtain an immune probe, and finally dropwise adding a phosphate buffer solution containing an antibody to be detected onto the immune substrate, and dropwise adding the immune probe solution to the immune substrate adsorbed with the antibody to be detected to obtain the sandwich structure immunosensor based on surface enhanced Raman scattering. The method has the advantages of high sensitivity, good selectivity and strong stability.
Owner:NINGBO FIRST HOSPITAL

Copper ion carrier material with photothermal effect, preparation method and anti-cancer drug formed by copper ion carrier material

The invention discloses a copper ion carrier material with a photothermal effect, a preparation method and an anti-cancer drug formed by the copper ion carrier material, and belongs to the technical field of nano drug loading technologies, and the structural formula of the copper ion carrier material is as follows: # imgabs0 #. The preparation method comprises the following steps: S1, mixing butanedione and concentrated hydrochloric acid in water, stirring and reacting, adding 4-methyl thiosemicarbazide, continuously stirring and reacting, and performing post-treatment to obtain a compound (4); then dissolving the compound (3) and 4, 4-dimethyl thiourea in a DMSO solvent, dropwise adding glacial acetic acid for reaction, and performing post-treatment to obtain a compound (6); dissolving the compound (6) and 6-aminocaproic acid in an acetonitrile solvent, reacting, and performing post-treatment to obtain a compound (8); and dissolving the compound (8) and beta-cyclodextrin in a DMSO solvent, mixing, adding an activating agent and a condensing agent, reacting, and performing post-treatment to obtain the copper ion carrier material with the photothermal effect. The problems that a copper ion carrier is poor in water solubility, low in photothermal conversion efficiency and low in near-infrared light energy, ultraviolet light is not prone to penetrating into tissues, and tissue damage can be caused are solved.
Owner:CHENGDU UNIV

Antagonists of the imidazoline-1 receptor for use in the prevention and / or treatment of an autoinflammatory or autoimmune disease

PCT designated stage expiredWO2025002914A1Amine active ingredientsCardiovascular disorderImidazoline receptorAutoimmune condition
The present invention refers to an antagonist of imidazoline-1 receptor (I1R) for use in the prevention and / or treatment of an autoinflammatory or autoimmune disease in a human subject, selected from the group consisting of (±)-2-endo-amino-3-exo- isopropylbicyclo[2.2.1]heptane (synonym: AGN192403), N-benzylguanidine, 2-(2- Fluoro-5-methylphenyl)-4,5-dihydro-1H-imidazole (synonym: S23757), 2-(2-chloro-4-iodo-phenylamino)-5-methyl-pyrroline (synonym: LNP911), 1-(4, 5-dihydro-1H-imidazol- 2-yl)isoquinoline (synonym: BU98008), 5-[2-bromophenoxy)methyl]-4,5-dihydro-1,3- oxazol-2-amine (synonym: S23515), 6-methylamino-2methylheptene (synonym: isometheptene), and 4-chloro-2,3-dihydro-2-oxo-1,3-benzothiazol-3-ylacetic acid (synonym: benazolin). Also, to the use of Imidazole propionate in the diagnosis of an autoinflammatory or autoimmune disease in a subject, and further to a method of diagnosis of atherosclerosis comprising assessing the level of ImP in a blood sample and determining whether said level is above or below a value of 41nM.
Owner:FUNDACION CENT NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III (CNIC)

Selective oxidation of 5-methylcytosine by TET-family proteins

The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.
Owner:CHILDRENS MEDICAL CENT CORP +1

Copper / titanium / TEOS (tetraethyl orthosilicate) rate selective control CMP (chemical mechanical polishing) solution based on TSV (through silicon via)

The invention relates to a TSV (through silicon via)-based copper / titanium / TEOS (tetraethyl orthosilicate) rate selective control CMP (chemical mechanical polishing) solution. The polishing solution is prepared from nanoscale silicon dioxide, a complexing agent, an inhibitor, a surfactant, an oxidizing agent and deionized water, the pH value of the alkaline polishing solution is 8.0; the invention discloses a polishing solution. 2, 2 '-[[((methyl-1H-benzotriazole-1-yl) methyl] imino] diethanol (TT-LYK) and octyl hydroxamic acid (OHA) are used as inhibitors, the two inhibitors act independently or are compounded, and under the synergistic effect of the inhibitors and the complexing agent, the polishing solution has the high polishing rate and the good surface quality performance, meanwhile, the rate of copper / titanium / TEOS can be selectively controlled, and the polishing effect is good. And dish-shaped recesses and dielectric layer erosion after polishing are improved. The polishing solution prepared by the invention is simple in preparation process and easy for large-scale production, and meets the actual requirements of industrial application.
Owner:河北工业大学创新研究院(石家庄) +1

Preparation method of photocuring methacrylated gelatin hydrogel dressing

The invention belongs to the technical field of dressing preparation, and particularly relates to a preparation method of a photocuring methacrylated gelatin hydrogel dressing, which comprises the following steps: step 1, dissolving methacrylated gelatin in a phosphate buffer solution to prepare a methacrylated gelatin solution with the mass concentration of 5-15%; 2, adding a natural photoinitiator into the solution obtained in the step 1, and uniformly stirring and mixing; 3, adding the traditional Chinese medicine active ingredient powder, and stirring until the powder is uniformly dispersed to obtain a mixed solution; and 4, pouring the mixed solution into a mold, and curing and molding under the irradiation of visible light. Chlorophyll or riboflavin is used as a natural photoinitiator and is directly dispersed in a methacrylated gelatin solution in a physical blending mode, a curing light source enables chlorophyll to completely avoid a chemical initiator, meanwhile, the process is simplified into physical stirring to replace nanoparticle synthesis and modification, visible light reduces the risk of tissue burn, the production cost is reduced, and the method is suitable for industrial production. The method is suitable for primary medicine.
Owner:咸宁市中心血站

Selective oxidation of 5-methylcytosine by TET-family proteins

The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.
Owner:CHILDRENS MEDICAL CENT CORP +1

Solid forms of a PARP7 inhibitor

The present invention relates to solid forms of the poly(ADP-ribose) polymerase 7 (PARP7) inhibitor 5-[[(2S)-1-(3-oxo-3-[4-[5-(trifluoromethyl)pyrimidin-2-yl]piperazin-1-yl]propoxy)propan-2-yl]amino]-4-(trifluoromethyl)-2,3-dihydropyridazin-3-one, and salts thereof, including methods of preparation thereof, where the inhibitor is useful in the treatment of cancer.
Owner:RIBON THERAPEUTICS INC

Dressing for diabetic foot wound and preparation method thereof

The invention relates to the technical field of biomedical dressings, in particular to a dressing for a diabetic foot wound surface and a preparation method of the dressing. 0.2 to 0.8 part of reduced graphene oxide; 2 to 5 parts of beta-1, 3-glucan modified by chondroitin sulfate; 0.08 to 0.3 part of silver nitrate; 3 to 7 parts of N-isopropyl acrylamide-co-acrylic acid; 0.15 to 0.4 part of N, N '-methylene bisacrylamide; 2 to 5 parts of sulfhydrylated hyaluronic acid; 0.3 to 0.8 part of D-alpha-vitamin E polyethylene glycol succinate; 2 to 5 parts of amino-functionalized mesoporous silica; 1 to 3 parts of L-arginine-L-glutamate; 0.1 to 0.4 part of genipin; the super-strong mechanical property and the super-strong flexibility are realized, so that the dressing can better adapt to the irregular shape of a wound surface, and continuous protection is provided.
Owner:THE FIRST AFFILIATED HOSPITAL OF ANHUI MEDICAL UNIV

Treatment of prostate cancer

Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof. Another method includes: administering once-daily to the subject in need thereof, an oral load dose formulation having from 240 mg to 480 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof, and thereafter administering once-daily to the subject, an oral maintenance dose formulation having 80 mg to 160 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.
Owner:TAKEDA PHARMA CO LTD +1

Selective oxidation of 5-methylcytosine by TET-family proteins

The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.
Owner:CHILDRENS MEDICAL CENT CORP +1

Preparation method of CETP inhibitor Obicetrapib (AMG-899)

The invention belongs to the technical field of chemical synthesis of medicines, and particularly relates to a preparation method of a CETP inhibitor Obicterapib. The invention provides three preparation schemes. According to the scheme I, 2-phenyl pentenoate and (R)-N-(1-phenethyl)-4-(trifluoromethyl) aniline are subjected to a reaction, and a target compound Obicterapib is prepared through hydrolysis, cyclization, acylation, asymmetric chiral amine and other multi-step reactions; according to the second scheme, 4-halogenated benzotrifluoride reacts with (R)-3-amino valeronitrile, then nitrile hydrolysis is carried out, the product reacts with ethyl chloroformate, bis (trifluoromethyl) benzyl bromide, bis (pinacolato) diboron and ethyl 4-bromobutyrate, and finally hydrolysis is carried out to prepare the target compound Obictapib. According to the third scheme, (R)-3-(4-trifluoromethyl-phenyl amino)-valeric acid is substituted by amino to obtain a compound (R)-3-[4-(trifluoromethyl) phenyl amino]-valeric acid amide, then the compound (R)-3-[4-(trifluoromethyl) phenyl amino]-valeric acid amide reacts with ethyl chloroformate, bis (trifluoromethyl) benzyl bromide, bis (pinacolato) diboron, ethyl 4-bromobutyrate and 5-bromine-2-chloropyrimidine, and finally hydrolysis is conducted to prepare the target compound Obictapib.
Owner:SHANGHAI XIANGHUI MEDICAL TECH

Kit for detecting anemia marker as well as preparation method and application of kit

The invention belongs to the field of clinical examination, and relates to a kit for detecting anemia markers as well as a preparation method and application of the kit. The method for detecting the anemia marker comprises the following steps: respectively adding an internal standard sample working solution into the series of calibration sample solutions, the series of quality control sample solutions and a serum sample, uniformly mixing, further adding a sample extraction solution, uniformly mixing, centrifuging, taking supernate, and carrying out LC-MS / MS detection on the supernate. In order to solve the technical problem that homocysteine, active folic acid, vitamin B12, methylmalonic acid and vitamin C cannot be simultaneously detected by a water-soluble vitamin detection method, a folic acid detection method, a methylmalonic acid detection method and the like in the prior art, the invention provides a detection method for simultaneously detecting the anemia marker.
Owner:SHANGHAI WANZI HEALTH MEDICAL LAB CO LTD